Emcure Pharmaceuticals Ltd. engages in developing, manufacturing and marketing of pharmaceutical products. It focuses on therapeutic areas, such as the gynecology, cardiovascular, Vitamins, minerals and nutrients, Anti-invectives, gastrointestinal, blood related oncology/anti-neoplastics, HIV, neurology, respiratory and anti-diabetic therapeutic areas. The company offers a wide range of products and services under Formulations, Biologics and Active Pharmaceutical Ingredients. It produces pharmaceutical and biopharmaceutical products of a range of dosage forms, including oral solids, oral liquids, injectables including lipid, liposomal, lyophilized injectables, biologics, vaccines and complex APIs, including chiral molecules and cytotoxic products. Emcure Pharmaceuticals was founded by Satish Ramanlal Mehta on April 16, 1981 and is headquartered in Pune, India.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company